Schedule 13D ownership disclosure

Stoke Therapeutics Inc

Common Stock, $0.0001 par value per share · CUSIP: 86150R107

Event date: 2024-12-23

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Blue Horizon Enterprise Ltd.

    Shares: 2,967,621 · Class: 5.6%

  • Ezbon International Limited

    Shares: 3,938,560 · Class: 7.4%

  • Montrago Trustees Limited

    Shares: 6,906,181 · Class: 13%

  • Skorpios TrustReported CIK 0001869333

    Shares: 6,906,181 · Class: 13%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001123292-24-000417
Form type
SCHEDULE 13D/A
Filer
Skorpios Trust
CIK
CIK 1869333
Filed
Dec 27, 2024
Reporting period
Dec 23, 2024
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub